NEW YORK (GenomeWeb) – Reaction Biology said today it has received a Small Business Innovation Research grant from the National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions.

The Malvern, Pa.-based company said it will use the $288,000 grant to study the interactions of more than 1,400 drugs and drug-like compounds that have been approved by the US Food and Drug Administration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.